Bulletin
Investor Alert

May 1, 2020, 4:06 a.m. EDT

Primary Biliary Cirrhosis- Global Market Outlook 2020 to 2030 | Albireo Pharma Inc, CymaBay Therapeutics Inc, Dr. Falk Pharma

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Albireo Pharma Inc. (ALBO)
  • X
    CymaBay Therapeutics Inc. (CBAY)
  • X
    Enanta Pharmaceuticals Inc. (ENTA)

or Cancel Already have a watchlist? Log In

May 01, 2020 Xherald -- Primary Biliary Cirrhosis Market Report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2030 .

Companies Covered

Albireo Pharma Inc /zigman2/quotes/204932368/composite ALBO -0.75% , CymaBay Therapeutics Inc /zigman2/quotes/201917619/composite CBAY +3.89% , Dr. Falk Pharma, Enanta Pharmaceuticals Inc /zigman2/quotes/209139157/composite ENTA +0.16% , Genextra, GenKyoTex SA (epa:GKTX), GlaxoSmithKline plc (lon:GSK), MediGene AG (etr:MDG1), NGM Biopharmaceuticals, Novartis AG (swx:NOVN), Shire, TGV-Laboratories, Virobay and others

Get Sample Copy of Primary Biliary Cirrhosis Market Report -

https://www.marketinsightsreports.com/reports/04282009711/primary-biliary-cirrhosis-market-insight-epidemiology-and-market-forecast-2030/inquiry/?Source=XH&mode=10

Markets Covered
United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2017-2030

Primary Biliary Cirrhosis Product Profiles & Analysis

This part of the Primary Biliary Cirrhosis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, and mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Primary Biliary Cirrhosis Market Share by Therapies

This section focuses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2030 . The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Primary Biliary Cirrhosis emerging therapies.

Reimbursement Scenario in Primary Biliary Cirrhosis

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Primary Biliary Cirrhosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Primary Biliary Cirrhosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Available discount@ ( Exclusive offer Upto 30%- Use code MIR 30):

/zigman2/quotes/204932368/composite
US : U.S.: Nasdaq
$ 25.14
-0.19 -0.75%
Volume: 77,955
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$379.43 million
Rev. per Employee
$326,667
loading...
/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 3.47
+0.13 +3.89%
Volume: 1.30M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$230.07 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/209139157/composite
US : U.S.: Nasdaq
$ 51.18
+0.08 +0.16%
Volume: 113,945
July 10, 2020 4:00p
P/E Ratio
45.72
Dividend Yield
N/A
Market Cap
$1.02 billion
Rev. per Employee
$2.11M
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.